CG Oncology, Inc. Common stock (CGON)
Automate Your Wheel Strategy on CGON
With Tiblio's Option Bot, you can configure your own wheel strategy including CGON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CGON
- Rev/Share 0.0072
- Book/Share 8.7943
- PB 4.6934
- Debt/Equity 0.0015
- CurrentRatio 22.153
- ROIC -0.2343
- MktCap 3147118906.0
- FreeCF/Share -1.2339
- PFCF -33.4604
- PE -36.3079
- Debt/Assets 0.0014
- DivYield 0
- ROE -0.131
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CGON | Guggenheim | -- | Buy | -- | $90 | Oct. 8, 2025 |
| Initiation | CGON | Piper Sandler | -- | Overweight | -- | $55 | Aug. 19, 2025 |
| Resumed | CGON | Goldman | -- | Buy | -- | $40 | July 10, 2025 |
| Initiation | CGON | JP Morgan | -- | Overweight | -- | $41 | May 2, 2025 |
| Initiation | CGON | Scotiabank | -- | Sector Perform | -- | $23 | April 16, 2025 |
| Initiation | CGON | TD Cowen | -- | Buy | -- | -- | Jan. 7, 2025 |
| Initiation | CGON | RBC Capital Mkts | -- | Outperform | -- | $66 | Sept. 23, 2024 |
| Initiation | CGON | ROTH MKM | -- | Buy | -- | $65 | Aug. 28, 2024 |
News
CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Positive
CG Oncology remains a compelling buy, driven by strong phase 3 data for its oncolytic virus therapy in bladder cancer. CGON's lead candidate, cretostimogene grenadenorepvec, achieved a 41.8% complete response rate at 24 months in high-risk NMIBC patients. CGON boasts a robust cash runway, supporting ongoing trials and potential regulatory delays, but FDA approval is not guaranteed and competition is intensifying.
Read More
CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
CG Oncology, Inc. (CGON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
CG Oncology, Inc. (NASDAQ:CGON ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Arthur Kuan - Chairman & CEO Ambaw Bellete - President & COO Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Okay. Good morning, everyone, and welcome to Morgan Stanley Global Healthcare Conference.
Read More
CG Oncology Stock Signals Bullish Momentum Ahead
Published: September 08, 2025 by: Benzinga
Sentiment: Positive
CG Oncology CGON has moved into Phase 2 of its 18-phase Adhishthana cycle, a critical stage that often sets the tone for early bullish momentum. Within this phase, the stock transitions into what's called the Buddhi move period, where breakouts are more likely to unfold.
Read More
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Positive
CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash position, providing a multi-year runway and reducing near-term dilution risk as it approaches potential commercialization. Key risk remains the lack of randomized data for FDA approval, but I view the likelihood of approval as high given the compelling clinical results.
Read More
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.
Read More
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
Read More
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Negative
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
Read More
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
Published: April 28, 2025 by: Benzinga
Sentiment: Positive
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
Read More
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
Read More
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
Published: April 02, 2025 by: Seeking Alpha
Sentiment: Positive
CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74.5% CR rate in the BOND-003 trial and a 41.2% CR rate in a phase 1 trial for MIBC. A basic DCF valuation estimates CGON's enterprise value at $5.3bn, suggesting a price target of $69, about 3x the current price.
Read More
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Read More
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET.
Read More
About CG Oncology, Inc. Common stock (CGON)
- IPO Date
- Website https://cgoncology.com
- Industry Biotechnology
- CEO Arthur Kuan
- Employees 113